SCHEMBL5098799

SCHEMBL5098799

O=C(NCCN1CCC(Oc2ccc(F)c(F)c2)CC1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 3/20 0.48
HRH3 Q9Y5N1 8/20 0.45
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
OPRD1 P41143 1/20 0.42
PLD2 O14939 2/20 0.41
PLD1 Q13393 2/20 0.41
HRH1 P35367 1/20 0.41
SLC5A7 Q9GZV3 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA1D P25100 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5102691 0.87 HRH3 (0.50) CCR3HRH3CARM1PRMT6PLD2
SCHEMBL5658226 0.84 DRD2 (0.49) CCR3HRH3CARM1PRMT6HRH1
SCHEMBL5102255 0.80 CARM1 (0.65) HRH3CARM1PRMT6
SCHEMBL7186721 0.79 CARM1 (0.45) CCR3HRH3CARM1PRMT6HRH1
SCHEMBL5657642 0.78 L3MBTL1 (0.42) CCR3HRH3PLD1HRH1GRIN1
SCHEMBL5655801 0.77 GPR6 (0.49) CCR3HRH3PLD2PLD1HRH1
SCHEMBL5099023 0.77 HRH3 (0.44) CCR3HRH3CARM1PRMT6HRH1
SCHEMBL5657759 0.76 HRH3 (0.53) CCR3HRH3OPRD1PLD2PLD1
SCHEMBL5654782 0.76 CCR3 (0.59) CCR3HRH3PLD2PLD1HRH1
SCHEMBL6403503 0.76 CCR3 (0.56) CCR3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348341-B2 Chemical compounds ASTRAZENECA AB (SE) 2008-03-25 US disclosed
US-20030166652-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-09-04 US disclosed
EP-1322611-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-07-02 EP disclosed
EP-1289956-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2002020484-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-03-14 WO disclosed
WO-2001092227-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166652-A1 Chemical compounds CCR3, CCR1, CCR4 CCR3 1/4885HRH3 471/4885CARM1 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.